ã¡ãã£ã¢èšäº
äžåœè£œã³ããã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ããºãææ°ããŒã¯ 115
twitterã³ã¡ã³ã 211ä»¶äž 1ïœ100件
äžåœå
񇜆
éŠè³éšã¯ã·ããã¡ãŒã ãæ¥çš®ãããã¡ã€ã¶ãŒè£œã¯ã¯ãã³ãæ¥çš®ããŠããŸãããèšãããããªã§ãã
ã¯ã¯ãã³ãå¹ããªãã®ãããããšãäžåœè£œã®ã¯ã¯ãã³ãå¹ããªãã®ããããã§ç¢ºèªã§ãããð
ãäœãã£ãŠãã®ã
ã·ããã¡ãŒã ã ãããäžå®ã§ãšããšããã¡ã€ã¶ãŒã®ãããŒã¹ã¿ãŒã·ã§ããïŒè¿œå æ¥çš®ïŒããéå§ãã¡ãã£ãäžæ±ããŒã¬ãŒã³ïœ¥ïœ¥ïœ¥ã
å¹ããªãã®ã«å®³ã ããæ®ã£ããææªã§ããããã
ã·ããã¡ãŒã ã ãããäžå®ã§ãšããšããã¡ã€ã¶ãŒã®ãããŒã¹ã¿ãŒã·ã§ããïŒè¿œå æ¥çš®ïŒããéå§ãã¡ãã£ãäžæ±ããŒã¬ãŒã³ïœ¥ïœ¥ïœ¥ã
å¹ããªãã®ã«å®³ã ããæ®ã£ããææªã§ããããã
äžæ±ããŒã¬ãŒã³ãäžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®
äžåœã®ã·ããã¡ãŒã ã2åæ¥çš®ãã人ã察象ã«ããã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã®è¿œå æ¥çš®ãéå§
äžåœã®ã·ããã¡ãŒã ã2åæ¥çš®ãã人ã察象ã«ããã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã®è¿œå æ¥çš®ãéå§
ããŒã¹ã¿ãŒã·ã§ããã£ãŠã
äžåœç³»ã¯ã¯ãã³ã«å¹æãªãã®ã蚌æãããŠããŠãã®èwww
ãã¡ããæ¥çš®åŸã«æ»ãã 人ãããããã ããå æé¢ä¿ã¯è©äŸ¡ã§ããŠãªãw
æ±äº¬ãªãªã³ããã¯ã§ã»ãŒå¹æãç¡ããšèšãããŠããã·ããã¡ãŒã ãã·ãããã¯ãæ¥çš®ããåœã
ã®éžæãã¹ã¿ãããã¯ã¯ãã³æ¥çš®æžã®å€§çŸ©ãæã£ãŠå
¥åœãããå±éºæ§ã£ãŠãã¹ãŽãã®ã©ããå ±éããŠãŸããïŒ
ã³ããã§åŒ±äœåãããŠã¯ã¯ãã³ã§ããã¡ãããšãåšå°ã ãª
äžåœã®ã¯ã¯ãã³å€äº€ãã
ãã®ã¯ã¯ãã³ãå¹ããªãéããŠãã»ãŒæ¥çš®ãçµãã£ããã©ææããšãŸããªãåœã§ããã¡ã€ã¶ãŒããããå床æã¡çŽããŠãåœããã©ãã©åºãŠããŠãŸããã©ãã
ããšå幎ãããçµã£ãããæè¬ã©ãããäœèšã«æãŸããçµæã«ãªã£ãŠãããã§ããã
ãã®ã¯ã¯ãã³ãå¹ããªãéããŠãã»ãŒæ¥çš®ãçµãã£ããã©ææããšãŸããªãåœã§ããã¡ã€ã¶ãŒããããå床æã¡çŽããŠãåœããã©ãã©åºãŠããŠãŸããã©ãã
ããšå幎ãããçµã£ãããæè¬ã©ãããäœèšã«æãŸããçµæã«ãªã£ãŠãããã§ããã
äž»ã«ã·ããã¡ãŒã 補ã®ã¯ã¯ãã³ã䜿çšãæ¥çš®çãé«ããã®ä»ã®åœã§ããææè
ãæ¥å¢ããæ·±å»ãªäºæ
ãçããŠãããã¢ã©ãéŠé·åœé£éŠïŒUAEïŒã¯ãã§ã«ããŒã¹ã¿ãŒã·ã§ãããéå§ãã»ãŒã·ã§ã«ããåæ§ã®æªçœ®ãæ€èš
Uncertain about the effect of Chinese corona vaccine, some countries of Pfizer's "reinoculation"
ãäžåœè£œã ãããã§ã¯ãªããŠãäžæŽ»åã¯ã¯ãã³ã ãããäžè¬çã«mRNAã¯ã¯ãã³ããæå¹æ§ãäœãå€ç°çš®ã«åŒ±ã
æå¹æ§50ïŒ ãªãããã¯ããŠã³è§£é€ãããã«æ²¿ã£ãŠç·©ããã«è¡ããªããšãŸããã ãã
æå¹æ§50ïŒ ãªãããã¯ããŠã³è§£é€ãããã«æ²¿ã£ãŠç·©ããã«è¡ããªããšãŸããã ãã
ã¯æ°åã³ãããŠã€ã«ã¹èºççãå
šäžçã«åºãã匵æ¬äººã ãããâŒïž
åãããªå£å©ããŠããã©ãããã«ã¯ä¿¡çšç¡ãã説åŸåããŒããâŒïž
æ¯èšãèèšã°ãããã»ãããªâŒïž
åãããªå£å©ããŠããã©ãããã«ã¯ä¿¡çšç¡ãã説åŸåããŒããâŒïž
æ¯èšãèèšã°ãããã»ãããªâŒïž
æ¯é£è£œã·ããã¡ãŒã ã³ããã¯ã¯ãã³ã¯å¹æã«çåã
æµç³ã«æ¯é£ã®ããããšã¯ãã€ãéçã«æåŸ ã«å¿ããŠããããã
æ°Žã®ã»ããå¹æããã®ã§ã¯ïŒ
æµç³ã«æ¯é£ã®ããããšã¯ãã€ãéçã«æåŸ ã«å¿ããŠããããã
æ°Žã®ã»ããå¹æããã®ã§ã¯ïŒ
ã·ãããã¯æã£ããã ãã©âŠ
è¥ãæ¹ãæäœãã§ãããããšãããã®ããªã
è¥ãæ¹ãæäœãã§ãããããšãããã®ããªã
äžççã«ãäžåœè£œã®ã¯ã¯ãã³ã¯ãã¯ã¯ãã³å€äº€ãã«äœ¿ãã ãã®å
šã圹ã«ç«ããªããã®ãšããæµãã«ãªã£ãŠãããã
äžåœãã®ãã®ãä»åŸå€§äžå€«ãªã®ããã
ã·ããã¡ãŒã ã®ã¯ã¯ãã³æ¥çš®ããŠãç§éã®åœã¯äºèŒªé¢ä¿è
å
šå¡æ¥çš®å®äºããŠãŸãŒãïŒãã£ãŠæ¥ãããŠãæããðŠãããéé¢æéãåžè¡ã®äžè¬ã®ããã«ã§éãããšä»æ¥ã®å ±éâŠæ¥æ¬äººäžè¬å®¢ãšäŒãã(ïŸoïŸ;;
ïŒã©ãããŠãRNAã¯ã¯ãã³ã«ããããããïŒæã¡çŽã
èšåºè©Šéšã®æéãå°ãªãã£ããšããŠããç²æ«ãããâŠ
åæ¥çš®ããªããšãããªããªãæå³ãªãããªã
äžåœè£œã¯å¹ããªãã¿ããã§ã ãªã¡ïŒ æåããåãã£ãŠããã©w ãããããæå¹æ²»çè¬ã§ããã€ãã«ã¡ã¯ãã³ã䜿ããããã«ååŽçã¯ãã¹ãã ïŒã€ã³ããæ²»ãŸã£ãå®çžŸãWHOã«å¯ŸããŠæ蚎ããŠããäºå®ãããã®ã ããâŠ
âäžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
âäžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ã€ã³ããŠã³ããå®å
šã«åŸ©æŽ»ãããçºã«ã¯äžåœäººãåŒã°ãªããšé£ãããšæããã ãã©ãã©ããããã ããã
ããŒã¬ãŒã³ã¯äººå£ã®50%ãã·ããã¡ãŒã ã®ã¯ã¯ãã³æ¥çš®ãçµãã£ãŠããããããã«ããŠææè
ãšæ»è
ãæ¥å¢ãæ¥éœãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã®åæ¥çš®ãéå§ãã·ãããã¯ã¯å€§äžå€«ãªã®ãïŒ
ã»ã¯ã¯ãã³ã®æ¥çš®çãæãé«ãæ°Žæºã«ãããªãããå§åçãªå¢ãã§ææè
ãæ¥å¢ããŠãã
ã»ååœã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ ã«éããŠãã
ã»ååœã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ ã«éããŠãã
äžåœã·ããã¡ãŒã 瀟ã¯ã¯ãã³ãïŒïŒïŒ
ã®åœæ°ãæ¥çš®ããåŸã«æææ¡å€§ã®ããŒã¬ãŒã³ãªã©ããã£ãªãã³ã®äºèŒªä»£è¡šã®å€§åãå瀟補ãã¯ã¯ãã³æã£ãŠäºèŒªã«æ¥ãããå®å¿ãšèšããã»ã©åçŽãªè©±ã§ã¯ãªãã
ðšð³ ãããããªãã§åšåŒµããªããäŒçµ±ã ããåšç¥ãããŠããã©ããã©ãã ãå²å²žäžéãªãã ãïŒèœåäœãäžã«å«ãããŠãã£ãŠå°ãã¯æãåã£ãŠããŠã®ãïŒãã£ã³ãã£ã©å¯ç¬ãããã ããð€£ð€£ð€£
äžåœè£œã¯ã¯ãã³ãæã£ãŠãããªã¯ææåæ¡å€§ããŠããã
ããŒã¬ãŒã³ã¯å¹ããªããŠãã¡ã€ã¶ãŒè£œãæã¡çŽããŠããã
ãããªã¯ã¯ãã³ã ã£ãŠç¥ã£ãŠããŠèšã£ãŠããã®ããªïŒ
è³è³ïŒ
ããŒã¬ãŒã³ã¯å¹ããªããŠãã¡ã€ã¶ãŒè£œãæã¡çŽããŠããã
ãããªã¯ã¯ãã³ã ã£ãŠç¥ã£ãŠããŠèšã£ãŠããã®ããªïŒ
è³è³ïŒ
Uncertain about the effect of Chinese corona vaccine, some countries of Pfizer's "reinoculation"
ãã£ã±ããªãâŠãð§
å¹ãç®ç¡ãã¯ã¯ãã³ãªãããã¡ãªããã ãã
æ¥æ¬ãã§ãªããå šäžççã«ã·ããã¡ãŒã ãªããŠåè延æããŠãã ãã¹ãã
ã¯ã¯ãã³æ¥çš®çãé«ãåœã§ææè ã»æ»è ãæ¥å¢ã®åå
äžåœè£œã³ããã¯ã¯ãã³ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
æ¥æ¬ãã§ãªããå šäžççã«ã·ããã¡ãŒã ãªããŠåè延æããŠãã ãã¹ãã
ã¯ã¯ãã³æ¥çš®çãé«ãåœã§ææè ã»æ»è ãæ¥å¢ã®åå
äžåœè£œã³ããã¯ã¯ãã³ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ãããªããšããŠå€§äžå€«ã§ããããïŒ
æå³ããã®ã§ããããïŒ
æå³ããã®ã§ããããïŒ
ææãåãŸããŸããçµå±ãã¡ã€ã¶ãŒã¯ã¯ãã³ãããŒã¹ã¿ãŒå©çšããªãããããªããšã¯ç®èãªããããª
äžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ãäžåœè£œã¯ã¯ãã³ã®æå¹æ§ã¯ã·ããã¡ãŒã 73%ãã·ãããã¯78ïŒ ãšãããŠããããèšåºè©Šéšå¯Ÿè±¡è ã®å€§åãè¥ãå¥åº·ãªç·æ§ã§ãããæ ¢æ§çŸæ£ããã人ã女æ§ãé«éœ¢è ãå«ãŸããŠããªãã
äžåœè£œã¯ã¯ãã³ãä¿¡çšãããªãæ以
ãäžåœè£œã¯ã¯ãã³ã®æå¹æ§ã¯ã·ããã¡ãŒã 73%ãã·ãããã¯78ïŒ ãšãããŠããããèšåºè©Šéšå¯Ÿè±¡è ã®å€§åãè¥ãå¥åº·ãªç·æ§ã§ãããæ ¢æ§çŸæ£ããã人ã女æ§ãé«éœ¢è ãå«ãŸããŠããªãã
äžåœè£œã¯ã¯ãã³ãä¿¡çšãããªãæ以
äžåœã®åœå¶ã·ããã¡ãŒã ïŒå»è¬éå£ç·å
¬åžïŒè£œã®ã¯ã¯ãã³ã®æå¹æ§ã«å¯Ÿããäžå®ãããŸããŸãé«ãŸã£ãŠããã
ãã®äºå®ããã£ãŠããããªåŠèšãã»ãããïŒ
ãã³ã³ã
mRNAã¯ã¯ãã³ã®å¹æã®é«ã
å¹æã®ãªããŽããè²·ããããåœã¯ææªãªç¶æ³ã«ãªã£ãŠãŸããã
äžåœè£œã¯ã¯ãã³ã®æå¹çã¯50ïŒ
ãè¶
ããçšåºŠãšèšãããŠãŸãããäžæŽ»åã¯ã¯ãã³ãªã®ã§ãã®ãããã®æå¹çã劥åœãªã®ãããããªãã
ããã ãmRNAã¯ã¯ãã³ã®æå¹çãé©ç°çïŒç°æ¬¡å ïŒãšããããšã
ããã ãmRNAã¯ã¯ãã³ã®æå¹çãé©ç°çïŒç°æ¬¡å ïŒãšããããšã
äžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ãŠã©ãŒã«ã»ã¹ããªãŒãã»ãžã£ãŒãã«ã«ãããšãåã³æ¥çš®ãåããããšãåçŽã«æããã«ãã人ã¯ããæ°å人ããã
ãã®äžã«ã¯ãã·ããã¡ãŒã ã®ã¯ã¯ãã³æ¥çš®ãåããåŸããæäœã確èªãããªãã£ã人ããããšããã
ãŠã©ãŒã«ã»ã¹ããªãŒãã»ãžã£ãŒãã«ã«ãããšãåã³æ¥çš®ãåããããšãåçŽã«æããã«ãã人ã¯ããæ°å人ããã
ãã®äžã«ã¯ãã·ããã¡ãŒã ã®ã¯ã¯ãã³æ¥çš®ãåããåŸããæäœã確èªãããªãã£ã人ããããšããã
ã»ããåºå
žå€æ°ã
ã·ããã¡ãŒã ãã·ãããã¯ãå¹æãªãã®ãå®èšŒãããŠããŸã£ããããªã
äžæåºãæ¥æ¬ãžã®èŒžå
¥ã䞻匵ããŠãããäžåœè£œã¯ã¯ãã³ã®å¹æããããªç¶æ³ã§ããïŒ
ãäžåœè£œã³ããã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ããŒã¬ãŒã³ã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ ã«éããŠãããããã«ããããããã人å£10äžäººåœããã®æ»è æ°ãã€ã³ããå€§å¹ ã«äžåã£ãŠããã
ããŒã¬ãŒã³ã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ ã«éããŠãããããã«ããããããã人å£10äžäººåœããã®æ»è æ°ãã€ã³ããå€§å¹ ã«äžåã£ãŠããã
ïŒååœã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ
ã«éããŠããããã®äžãã·ããã¡ãŒã 補ã®ããŒã¹ã¿ãŒã·ã§ããããã§ã«éå§ããŠãããããã«ããããããã人å£10äžäººåœããã®æ»è
æ°ãã€ã³ãã倧å¹
ã«äžåã£ãŠ
äžè¯ã¯ã¯ãã³å€§éå°å
¥ã®åœã¯ä»ã«ãå€ããããã€ã³ããã·ã¢ã»ã©ãªã¹ã»ã«ã³ããžã¢ã¯ãä»åŸã©ãæšç§»ããŠããã®ãæ°ã«ãªããŸãã
ããã»ã¹ã®éææ§ãä¿ã€ã®ã¯ãèŠæäžã®èŠæãã®åœã ããããã䞡瀟ã䞻匵ããæå¹æ§ãæ€èšŒããããã«å¿
èŠãªèšåºããŒã¿ãäžè¶³ããŠããã»ããå
¬éãããŠããããŒã¿ã«äžåãããã
ãŸãæ±åŽã ãããã
( ÂŽâ¢à±ªâ¢`)ã£å®ãããæ©ãããæªãããã®å®äŸïŒç¬âŠããªãïŒ
äžè¯ïŸïœžïŸïŸæ¥çš®ã§å¯§ãå€ç°æ ªææå¢ãããšããªããããªâŠãããã§æããð¥¶
äžè¯ïŸïœžïŸïŸæ¥çš®ã§å¯§ãå€ç°æ ªææå¢ãããšããªããããªâŠãããã§æããð¥¶
å¹ãå¹ããªã以åã«ããã¡ããšå質管çåºæ¥ãŠãããã®æ¹ãäžå®ã«ãªããã¥ãŒã¹ã
æææå¶å¹æã©ãããéçåã®æå¶ãåºæ¥ãªããšãªããšã足ããŠããªãå質ã®ãã®ã倧éçç£ããŠããã®ã§ã¯ãªãããšããç念ãã
æææå¶å¹æã©ãããéçåã®æå¶ãåºæ¥ãªããšãªããšã足ããŠããªãå質ã®ãã®ã倧éçç£ããŠããã®ã§ã¯ãªãããšããç念ãã
ïŒ ã
UAEãå°ã£ãŠãããšèããŸãããã
UAEãå°ã£ãŠãããšèããŸãããã
äžè¯è£œã®ã¯ã¯ãã³ãªããä¿¡çšããæ¹ãããããã§ãã
[ç¶ã]床ç®ã®é倧ãªé倱ãç¯ããããšã«ãªãã
äžå®ãšããããããæã€æ°ã«ãªããªã
æããŠæãŠããã
é»è³åããããã ããªã
æããŠæãŠããã
é»è³åããããã ããªã
æ¿æ²»çã«ã¯ãã³ãããã¯ãŠã€ã«ã¹ã®çºçå°ãšãªã£ãããšãããé
ããŸãã£ãã¯ã¯ãã³ã®å¹æãä»ã²ãšã€ã ã£ã圱é¿ã®æ¹ã倧ãããªãããç¥ãããã
äžåœè£œã³ããã¯ã¯ãã³ã·ããã¡ãŒã ã®å¹æã«äžå®ãã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ã¯ã¯ãã³ã®æ¥çš®çãæãé«ãæ°Žæºã«ãããªããã人å£10äžäººåœããã®æ»è æ°ãã€ã³ããå€§å¹ ã«äžåããææè ãæ¥å¢ããŠããããŒã¬ãŒã³ã¯ãã·ããã¡ãŒã 補ã¯ã¯ãã³ãå®äºãã人ã察象ã«ãç±³ãã¡ã€ã¶-
ã¯ã¯ãã³ã®æ¥çš®çãæãé«ãæ°Žæºã«ãããªããã人å£10äžäººåœããã®æ»è æ°ãã€ã³ããå€§å¹ ã«äžåããææè ãæ¥å¢ããŠããããŒã¬ãŒã³ã¯ãã·ããã¡ãŒã 補ã¯ã¯ãã³ãå®äºãã人ã察象ã«ãç±³ãã¡ã€ã¶-
ããã£ïŒããŒã¹ã¿ãŒã·ã§ããã ãïŒ
å¹ããªãäžã«ïœ¢ã¯ã¯ãã³æã£ããïŒãŠã§ãŒã€ïœ£å¹æã§ã絶è³æææ¡å€§äžã®ãæ»ã®ãã¡ãŒã ãã
éã«ã¯ä»ç€Ÿã®ã¯ã¯ãã³ã®ããŒã¹ã¿ãŒã·ã£ãããŸã§å§ããŠããå§æ«ãæ§ããã«èšã£ãŠã¯ãœïŒ
éã«ã¯ä»ç€Ÿã®ã¯ã¯ãã³ã®ããŒã¹ã¿ãŒã·ã£ãããŸã§å§ããŠããå§æ«ãæ§ããã«èšã£ãŠã¯ãœïŒ
ä»®ã«åšå€äžåœäººã«æ¥çš®ããã¯ã¯ãã³ãã·ããã¡ãŒã 補ã«ããŠãWHOã¯æå¥ã¯èšããªããå·®å¥ã«ã¯åœãããªãã¯ãããããéå£å
ç«ã®ç²åŸã«è³ãããã¯ç¥ãããã
æåã¯ããææããªããšèšã£ãŠããWHOã®å¹¹éšçãªäººãç©æ¥µçã«ã·ããã¡ãŒã 補ã¯ã¯ãã³ãæã£ãŠã»ãããã®ã ã
æåã¯ããææããªããšèšã£ãŠããWHOã®å¹¹éšçãªäººãç©æ¥µçã«ã·ããã¡ãŒã 補ã¯ã¯ãã³ãæã£ãŠã»ãããã®ã ã
äžåœãšããŠã¯ãã¡ã¯ããäžæŽ»åã¯ã¯ãã³ãäžçã«å£²ã蟌ãã§é¢ç®èºåŠãšããããã£ããšãããªãã ãããã©ãmRNAã¯ã¯ãã³ã®ç»å Žã§ãã£ããéãããã£ãããâŠ
ããŠãäžåœè£œã®ãã¯ã¯ãã³å€äº€ããåãå
¥ããåœã
ã§ææåæ¡å€§ããŠãã®ã¯ãã©ãã®åœã
ããªïŒð
â¡ïž
äžåœã®åœå¶ã·ããã¡ãŒã (å»è¬éå£ç·å ¬åž)補ã®ã¯ã¯ãã³ã®æå¹æ§ã«å¯Ÿããäžå®ãããŸããŸãé«ãŸã£ãŠããã
â¡ïž
äžåœã®åœå¶ã·ããã¡ãŒã (å»è¬éå£ç·å ¬åž)補ã®ã¯ã¯ãã³ã®æå¹æ§ã«å¯Ÿããäžå®ãããŸããŸãé«ãŸã£ãŠããã
ããè¿å¹ããªãã¯ã¯ãã³ãªã埡å®ããšåãã§ãã
äžåœã¯ããªãè¿œã蟌ãŸããŠããªãäžåœã®å³æ¹ããåœã絶æ»
ããŠãããã
äžå
±ã¯ã¯ãã³ã¯æå¹æ§ãäœãããâ
ããŒã¬ãŒã³ã¯6æ3æ¥ãã§ã«ã·ããã¡ãŒã 補ã¯ã¯ãã³ã®2åã®æ¥çš®ãå®äºãã人ã察象ã«ãç±³ãã¡ã€ã¶ãŒãšç¬ããªã³ããã¯ãå
±åéçºããã¯ã¯ãã³ã®ãããŒã¹ã¿ãŒã·ã§ããïŒè¿œå æ¥çš®ïŒããéå§ããããšãæããã«ãã
ããŒã¬ãŒã³ã¯ãã¯ã¯ãã³æ¥çš®çãæãé«ãæ°Žæºã«ããããå§åçãªå¢ãã§ææè
ãæ¥å¢ããŠãããããã§ïœãäžåœã·ããã¡ãŒã 補ã¯ã¯ãã³ã®2åç®ã®æ¥çš®ãå®äºãã人ã察象ã«ãç±³ãã¡ã€ã¶ãŒããç¬ããªã³ããã¯ãå
±åéçºããã¯ã¯ãã³ã®è¿œå æ¥çš®ãéå§ãããããã®ã§ããã»ã»ã»
å®å®ã®äžåœè£œãå¹æç¡ããæ°åã§äžãã£ãã
ããããçŸå®ãèŠããã
æ¥æ¬ãå°æ¹Ÿã«éã£ãã¢ã¹ãã©ãŒãã«è£œã¯ã¯ãã³ããäžåœã§ã¯è¡æ åé¡ã§æ¥æ¬ã§äžèŠãšãªã£ãåãæ¿æ²»å©çšããã ããšã®æ¹å€ããããäžåœã·ããã¡ãŒã 補ããã¯é¥ãã«åªããŠãããé«éœ¢è
ã§è¡æ ã®äŸã¯ç¡ãã
äžåœã¯ã¯ã¯ãã³ãäŸçµŠããããšã«ãããäžçã®ãã¯ãŒãã©ã³ã¹ã®ã€ãã·ã¢ãããåãã€ããã ã£ããã ãããªã
æ倧ã®èª€ç®ã¯mRNAã¯ã¯ãã³ãšãããäŒå µããé©ç°çãªå¹æãçºæ®ããŠãåŸæ¥åäžæŽ»æ§ã¯ã¯ãã³ã§ããã·ããã¡ãŒã ã¯ã¯ãã³ã¯äºæµåã®çå°ãæŒãããŠããŸã£ãããšã
æ倧ã®èª€ç®ã¯mRNAã¯ã¯ãã³ãšãããäŒå µããé©ç°çãªå¹æãçºæ®ããŠãåŸæ¥åäžæŽ»æ§ã¯ã¯ãã³ã§ããã·ããã¡ãŒã ã¯ã¯ãã³ã¯äºæµåã®çå°ãæŒãããŠããŸã£ãããšã
äžåœè£œã¯ã¯ãã³ã¯æ»éªžããäœãããããªãâŠå¹ãç®ãèãã®ãâŠ
æ¥æ¬ã§ãç«æ²æ°äž»å
ãæ¿æš©ã®åº§ã«ããããäžåœè£œã¯ã¯ãã³ã®å°å
¥ã蚎ããäžæåºãšãã®æèŠãçã«åããŠãä»ã®ããŒã¬ãŒã³ã¿ããã«ãªã£ãŠããå¯èœæ§ããã£ããã ããªãæ¬åœã«ãã®æ¿å
ãäžå
ã§ãªãç¶æ³ã¯å¥åã ãšæããªã
IOCã®äŒé·ã¯äžåœç£ã®ã¯ã¯ãã³ãåå è
ã«æäŸããã£ãŠèšã£ãŠãªãã£ãã£ãâŠ
æå¹ç50%ã確ä¿åºæ¥ãŠãªãã£ãœããªããWHOãããæ¿èªããããã ã
äžåœã¯èªåœæ°ã«ããã®ã¯ã¯ãã³äœ¿ããã ãããã
äžåœã¯èªåœæ°ã«ããã®ã¯ã¯ãã³äœ¿ããã ãããã
æ¿èªããWHOã«ã¯äžä¿¡æãããªã âŠ
ããã«ã€ããŠèª¬æãããå®æ掲
ãããããããã¬ã¡ãã£ãð
ãã£ã€ãã¯ã¯ãã³ãå¥ã«å¹ããªããããããªããŠmRNAã¯ã¯ãã³ã®å¹æãç°æ¬¡å
ã¬ãã«ãªã®ã ãšç解ããŠãã
ããããããšåãªãå¡©æ°Žãããããã
æµç³ã«ããã¯ãªããšä¿¡ãããâŠãã圌ã®åœã¯ããããä¿¡çšããªã
éã£ãŠããæããŠãã ãã
ããããããšåãªãå¡©æ°Žãããããã
æµç³ã«ããã¯ãªããšä¿¡ãããâŠãã圌ã®åœã¯ããããä¿¡çšããªã
éã£ãŠããæããŠãã ãã
ãã®è©±ãšã¯é¢ä¿ãªãã§ãããïŒãã®æå¥ã¯WHOãžã©ããã
å®ç©è²·ãã®âŠ
äžåœè£œã¯ã¯ãã³ã®æå¹æ§ã¯ããããã50%ããããšããã®ããä»ã®ãšããã®ã³ã³ã»ã³ãµã¹ããæ±äº¬äºèŒªã§å€åœããã®éžæãšé¢ä¿è
ã¯ã¯ã¯ãã³ãæ¥çš®ããŠããããå®å
šããšããã®ã¯å
šãä¿¡çšã«ãªããªãã§ããã
äžè¯ã¯ã¯ãã³ïŒãã ã®ççé£å¡©æ°Žã§ããïŒïŒïŒ
äž»ã«ã·ããã¡ãŒã 補ã®ã¯ã¯ãã³ã䜿çšããæ¥çš®çãé«ããã®ä»ã®åœã§ããææè
ãæ¥å¢ããæ·±å»ãªäºæ
ãçããŠãããã¢ã©ãéŠé·åœé£éŠã¯ãã§ã«ããŒã¹ã¿ãŒã·ã§ãããéå§ãã»ãŒã·ã§ã«ãåæ§ã®æªçœ®ãæ€èšããŠãã
ããŒã¬ãŒã³ã§æ¥çš®ãå®äºãã人ã®å²åã¯ãããã50ïŒ
ãããã«ã·ããã¡ãŒã 補ã®ããŒã¹ã¿ãŒã·ã§ãããéå§ããã«ããããããã人å£10äžäººåœããã®æ»è
æ°ãã€ã³ãã倧å¹
ã«äžåã£ããšã®ããšã
ïŒæ¥çš®çãæãé«ãæ°Žæºã«ãããªãããå§åçãªå¢ãã§ææè
ãæ¥å¢ããŠããããŒã¬ãŒã³ã¯ããã§ã«ã·ããã¡ãŒã 補ã¯ã¯ãã³ã®2åã®æ¥çš®ãå®äºãã人ã察象ã«ãç±³ãã¡ã€ã¶ãŒãšç¬ããªã³ããã¯ãå
±åéçºããã¯ã¯ãã³ã®ãããŒã¹ã¿ãŒã·ã§ããïŒè¿œå æ¥çš®ïŒããéå§ããâŠ
(;ÂŽÐŽïœ)
(;ÂŽÐŽïœ)
ãã®ã³ããã®çœçŠã«äººã®äžå®ã«ã€ã蟌ãã§ãŽãã売ãã€ããŠãŒãå²ããäŒãããŸãã«å€éã
äžåœãªããŠè©æ¬ºåž«ãããŽããè²·ã£ãŠããŸã£ãåœã¯ããããèŠåŽããäºã«ãªãèš³ã ã
äžåœãªããŠè©æ¬ºåž«ãããŽããè²·ã£ãŠããŸã£ãåœã¯ããããèŠåŽããäºã«ãªãèš³ã ã
ããŒã¬ãŒã³ãäžè¯è£œã®ã¯ã¯ãã³æ¥çš®ç50ïŒ
ã«ãªã£ãã®ã«ã人å£10äžäººåœããã®æ»è
ãã€ã³ããè¶
ãããããã
ã¯ã¯ãã³ãããªããŠãŠã€ã«ã¹ãããªãã®ããªã
ã¯ã¯ãã³ãããªããŠãŠã€ã«ã¹ãããªãã®ããªã
éå
ããªããæ¿èªããããã«è¿«ã£ãŠãããäžåœè£œã¯ã¯ãã³ãæ¥çš®ããçµæãããã
"
"
Sinopharmã¯ã¯ãã³ã®è²©å£²å䟡ãäœæ
ãAZã¯ã¯ãã³ããé«ããPfizer/BioNTechã¯ã¯ãã³ããå°ãå®ãçšåºŠãšãã話ãæµåžããŠããŸããã©ãã©ããªãã§ããããã
>èšåºè©Šéšã¯å¯Ÿè±¡è
ã®å€§åãè¥ãå¥åº·ãªç·æ§ã§ãããæ
¢æ§çŸæ£ããã人ã女æ§ãé«éœ¢è
ãå«ãŸããŠããªãã
å¹æããªãã£ãã ããŸã ããã£ããšæããç¬ æ¥çš®ããŠæ°ã¶æåŸã«äœãèµ·ãããåãããªããããç¬
ããŒã¬ã³å€§å€ã ãªãã æ¯é£ç£ã¯ã¯ãã³ãå¹ããªãããå幎åŸã«ãã¡ã€ã¶ãŒè£œããŸãæããªããã°ãªããªãã®ã
äžåœè£œã¯ã¯ãã³ã®å¹æã«äžå®ããã¡ã€ã¶ãŒè£œãåæ¥çš®ãã®åœã
ãäžåœè£œã¯ã¯ãã³ã®æå¹æ§ã¯ã·ããã¡ãŒã 73%ãã·ãããã¯78ïŒ ãšãããŠããããèšåºè©Šéšå¯Ÿè±¡è ã®å€§åãè¥ãå¥åº·ãªç·æ§ã§ãããæ ¢æ§çŸæ£ããã人ã女æ§ãé«éœ¢è ãå«ãŸããŠããªãã
äžåœè£œã¯ã¯ãã³ãä¿¡çšãããªãæ以
ãäžåœè£œã¯ã¯ãã³ã®æå¹æ§ã¯ã·ããã¡ãŒã 73%ãã·ãããã¯78ïŒ ãšãããŠããããèšåºè©Šéšå¯Ÿè±¡è ã®å€§åãè¥ãå¥åº·ãªç·æ§ã§ãããæ ¢æ§çŸæ£ããã人ã女æ§ãé«éœ¢è ãå«ãŸããŠããªãã
äžåœè£œã¯ã¯ãã³ãä¿¡çšãããªãæ以
äžåœè£œã§ã¯ä¿¡çšã§ããªããâšäžåœè£œã¯ã¯ãã³æ¥çš®ãå®äºãã人ã®å²åã¯ãããŒã¬ãŒã³ã®ããã50ïŒ
ã«éããŠããããã®äžãã·ããã¡ãŒã 補ã®ããŒã¹ã¿ãŒã·ã§ããããã§ã«éå§ããŠãããããã«ããããããã人å£10äžäººåœããã®æ»è
æ°ãã€ã³ãã倧å¹
ã«äžåã£ãŠãã
ãïœïœã»ã»ã»å°æ¹Ÿè¯ãã£ããã£ãŠããšããªã
å®ç©è²·ãã®é倱ãã
åæ¥çš®ããåœãå¢ããŠãã ãããã
ããŒã¬ãŒã³ã¯äžåœè£œã¯ã¯ãã³2åæ¥çš®å®äºè ã察象ã«ããã¡ã€ã¶ãŒãã¯ã¯ãã³è¿œå æ¥çš®ãããšã®äºã
æ¬åœãæ¥æ¬ã¯ã¯ã¯ãã³ç¢ºä¿ã®é¢ã§æµãŸããŠããããæ¿åºã¯Good Jobã ãã
ããŒã¬ãŒã³ã¯äžåœè£œã¯ã¯ãã³2åæ¥çš®å®äºè ã察象ã«ããã¡ã€ã¶ãŒãã¯ã¯ãã³è¿œå æ¥çš®ãããšã®äºã
æ¬åœãæ¥æ¬ã¯ã¯ã¯ãã³ç¢ºä¿ã®é¢ã§æµãŸããŠããããæ¿åºã¯Good Jobã ãã
äžåœè£œåã«é¢ããŠã¯ãWHOãæ¿èªããããšãæãä¿¡çšã§ããªãã ãã
å㞠次ãž